Monoclonal antibody utilization characteristics in patients with multiple myeloma
| Autor: | Sikander Ailawadhi, Abdel Ghani Azzouqa, Victoria R. Alegria, Vishal S. Shah, Meghna Ailawadhi, Vivek Roy, Rafael Fonseca, David O. Hodge, Nancy N. Diehl, Zahara Meghji, Tania Jain, Asher Chanan-Khan, Prachi Jani, Aneel Paulus, Taimur Sher, Salman Ahmed |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Neutropenia Antibodies Monoclonal Humanized 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Pharmacology (medical) Elotuzumab Adverse effect Survival rate Aged Pharmacology Aged 80 and over Salvage Therapy business.industry Incidence Daratumumab Antibodies Monoclonal Middle Aged medicine.disease Prognosis United States Clinical trial Survival Rate 030104 developmental biology Oncology Drug Resistance Neoplasm 030220 oncology & carcinogenesis Monoclonal Premedication Female Neoplasm Recurrence Local business Multiple Myeloma medicine.drug Follow-Up Studies |
| Zdroj: | Anti-cancer drugs. 30(8) |
| ISSN: | 1473-5741 |
| Popis: | This study analyzed 91 multiple myeloma patients who received two monoclonal antibodies, Daratumumab and Elotuzumab, over a year and report the adverse event profile, infusion practices and utilization of these drugs in the real world. All current reported data on monoclonal antibodies is from clinical trials, without any real-world experience. Patients from Mayo Clinic Florida or Arizona diagnosed with relapsed or refractory multiple myeloma who were treated with Daratumumab or Elotuzumab alone or in combination between 1 January 2016 and 31 December 2016 were included in the analysis. Daratumumab-treated patients (n = 78) were more heavily pre-treated than that in published clinical trials, whereas the elotuzumab patient (n = 13) profile was similar to that published before. Infusion time was on average 2 hours less than the prescribing guidelines and premedication use varied noticeably after the initial monoclonal antibody infusion, with an overall decrease over time. We noted higher than reported haematologic adverse events, especially neutropenia and fewer non-haematologic adverse events. 91.7% infusion-related reactions were observed during the first monoclonal antibody infusion, with a subsequent decrease. All infusion-related reactions were grade 2 or less, and none of the patients discontinued treatment due to infusion-related reactions. Baseline allergy profile or laboratory tests were not associated with the likelihood of developing monoclonal antibody-related infusion-related reactions. The real-world safety profile of monoclonal antibodies showed varying adverse event patterns than those reported in previous clinical trials. The infusion-related reaction patterns were similar to previous reports. Despite changes in premedication regimens safety was maintained in succeeding infusions. Such treatment utilization data is vital to broaden our knowledge of approved therapeutic agents and maximize their benefits for patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|